ArticleMolecular neurobiology2026
A Protective Role of Hydrogen Sulfide Donor GYY4137 Through Activated Microglia-induced Anti-inflammatory Cytokines in the Spinal Cord of Diabetic Rats.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing significance of inflammation in the pathophysiology of diabetes and its complications, such as diabetic peripheral neuropathy, has generated significant interest in targeting inflammation for disease prevention and control. Hydrogen sulfide (H₂S) has emerged as a promising therapeutic candidate due to its regulatory role in neuroinflammation. The present study investigated the anti-inflammatory effects of prolonged treatment with H₂S donor GYY4137 on microglial and astrocyte activation, along with the subsequent release of anti-inflammatory cytokines, including interleukin (IL)-4, IL-10, IL-13, transforming growth factor-beta (TGF-β), and arginase-1, in the spinal cords of streptozotocin-induced diabetic male rats. We also examined the effect of GYY4137 on signal transducer and activator of transcription 3 (STAT3) and the expression of pro-inflammatory cytokine IL-12. STAT3 is crucial for cytokine release signaling and microglial polarization, while IL-12 is a key marker of inflammation severity in diabetes. GYY4137 treatment effectively suppressed microglial activation, STAT3 activation, and IL-12 expression, while significantly increasing the secretion of anti-inflammatory cytokines in diabetic rats during weeks 4, 8, and 10 post-treatments. Our previous work demonstrated that 4-week-GYY4137 treatment suppressed pro-inflammatory cytokines in diabetic rats. Here, we show that prolonged GYY4137 treatment facilitated microglial transition from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype. The treatment also prevented the loss of astrocytes and neuronal cells in the spinal cord, indicating neuroprotective effects. In conclusion, our findings suggest that H₂S can shift microglial activity from neuroinflammation to neuroprotection, highlighting its potential as a possible candidate for novel therapeutic strategy for diabetes and its complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.